Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)

Trial Profile

Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laromestrocel (Primary)
  • Indications Hypoplastic left heart syndrome
  • Focus Adverse reactions
  • Acronyms ELPIS; ELPIS I
  • Sponsors Longeveron

Most Recent Events

  • 27 Oct 2024 According to a Longeveron media release, data from this study were presented at the Congenital Heart Surgeons Society (CHSS) 51st Annual Meeting taking place October 27-28, 2024 in Chicago, Illinois.
  • 27 Oct 2024 Results presented in a Longeveron Media Release.
  • 09 Oct 2024 According to a Longeveron media release, Based on the strength of the ELPIS I data company is conducting the ELPIS II Phase 2b clinical trial, which is evaluating cellular therapy Lomecel-B as a potential adjunct therapy for treating HLHS, and which, if positive, may serve as the foundation for a BLA submission for potential approval of Lomecel-B.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top